| Literature DB >> 24336127 |
J Nakata1, K Nakano2, A Okumura2, Y Mizutani2, H Kinoshita2, M Iwai2, K Hasegawa3, S Morimoto3, F Fujiki3, N Tatsumi4, H Nakajima3, Y Nakae1, S Nishida5, A Tsuboi5, Y Oji4, Y Oka6, H Sugiyama2, A Kumanogoh6, N Hosen7.
Abstract
It remains unclear how the immune system affects leukemia development. To clarify the significance of the presence of immune systems in leukemia development, we transferred MLL/ENL leukemia cells into immune-competent or immune-deficient mice without any preconditioning including irradiation. The wild-type mice did not develop leukemia, whereas all the Rag2(-/-)γc(-/-) mice lacking both adaptive immune cells and natural killer (NK) cells developed leukemia, indicating that leukemia cells were immunologically rejected. Interestingly, leukemia cells were also rejected in 60% of the Rag2(-/-) mice that lacked adaptive immune cells but possessed NK cells, suggesting that NK cells play a substantial role in the rejection of leukemia. Moreover, engraftment of leukemia cells was enhanced by NK cell depletion in Rag2(-/-) recipients and inhibited by transfer of NK cells into Rag2(-/-)γc(-/-) recipients. Upregulation of NKG2D (NK group 2, member D) ligands in MLL/ENL leukemia cells caused elimination of leukemia cells by NK cells. Finally, we found that leukemia cells resistant to elimination by NK cells had been selected during leukemia development in Rag2(-/-) recipients. These results demonstrate that NK cells can eradicate MLL/ENL leukemia cells in vivo in the absence of adaptive immunity, thus suggesting that NK cells can play a potent role in immunosurveillance against leukemia.Entities:
Mesh：
Substances：
Year: 2013 PMID： 24336127 DOI： 10.1038/leu.2013.374
Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528